Sage Journals: Discover world-class research

Abstract

Multiple endovascular interventions exist for the treatment of lower extremity peripheral arterial disease (PAD), with some exhibiting better outcomes than others. As these procedures become more numerous and accepted, the type of interventionalist providing the care is changing. Despite advances in technology and techniques, there are many obstacles to overcome in order to improve the treatment of patients with vascular disease. These can be divided into managing recurrent disease, protection of the distal vasculature, and the prevention of disease. Studies are already underway in areas involving drug-eluting balloons and stents for the periphery, brachytherapy, bioabsorbable stents, distal protection, and therapeutic angiogenesis. As knowledge about the treatment of peripheral arterial disease is acquired that can be applied to the concept of personalized health care, there is hope to be able to slow or arrest the progression of this disease.

Keywords

peripheral arterial disease lower extremity intervention personalized health care

Get full access to this article

View all access options for this article.

References

Goodney P. , Beck A. , Nagle J. , Welch H. , Zwolak R. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009;50: 54-60.

Peripheral Arterial Disease (PAD) Coalition. Inaugural meeting summary; NIH, Bethesda, Maryland, June 17, 2004.

Duda S. , Bosiers M. , Lammer J. , et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701-710.

Duda S. , Bosiers M. , Lammer J. , et al. Sirolimus-eluting versus bare metal nitinol stents for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331-338.

Cook Medical. Zilver PTX stent from Cook Medical gains CE mark [press release]. August 11, 2009.

Tepe G. , Zeller T. , Albrecht T. , et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. New Engl J Med. 2008;358:689-699.

Hansrani M. , Overbeck K. , Smout J. , Stansby G. Intravascular brachytherapy for peripheral vascular disease. Cochrane Database Syst Rev. 2002;(4):CD003504.

Niimi S. , Harashima M. , Hyuga M. Current status of therapeutic angiogenesis with protein, gene, and cell therapy . Curr Drug Ther. 2009;4:221-233.

Rajagopalan S. , Mohler E. , Lederman R. , et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double blind, controlled study of a adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108: 1933-1938.

10.

Lederman R. , Mendelsohn F. , Anderson R. , et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial. Lancet. 2002;359:2053-2058.

11.

Personalized Health Care Expert Panel Meeting: Summary Report. Submitted to: US Department of Health and Human Services by the Lewin Group, Inc, September 10, 2007.

On the Horizon: What’s Coming Next for Lower Extremity Interventions

Abstract

Keywords

Get full access to this article

References